Jounce Therapeutics, Inc.
JNCEDelisted May 4, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640455
Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 84
- Q1 2023, 0 vs. previous quarter
- 13F value
- $64.1M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding JNCE, Q1 2023
No superinvestor reported holding JNCE at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Jounce Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 (view filing) | Apr 4 | 2 days | Murray RichardDirector | SSale | −39.2K | $1.85 | −$72.6K | −17.2%188.8K after | 10b5-1 |
| Mar 14, 2023 (view filing)8:39 PM ET | Mar 13-14 | 1 day | Tang Kevin C and 2 others10% Owner | PPurchase | +86.0K | $0.9997 | +$86.0K | +1.6%5.30M after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9-10 | 2 days | Trehu ElizabethChief Medical Officer | SSale | −9.29K | $1.11 | −$10.3K | −8.2%103.4K after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9-10 | 2 days | Murray RichardCEO and President | SSale | −45.1K | $1.11 | −$50.1K | −16.5%228.0K after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9-10 | 2 days | Drapkin Kimberlee CCFO and Treasurer | SSale | −14.1K | $1.11 | −$15.7K | −17.6%66.0K after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9-10 | 2 days | Cole Hugh MChief Operating Officer | SSale | −16.6K | $1.11 | −$18.5K | −13.1%110.1K after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 7-10 | 4 days | Trehu ElizabethChief Medical Officer | SSale | −8.38K | $6.88 | −$57.7K | −9.0%85.2K after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 7-10 | 4 days | Murray RichardCEO and President | SSale | −37.3K | $6.88 | −$256.7K | −16.7%185.6K after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 7-10 | 4 days | Drapkin Kimberlee CCFO and Treasurer | SSale | −12.8K | $6.88 | −$88.2K | −19.6%52.6K after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 7-10 | 4 days | Cole Hugh MChief Business Officer | SSale | −9.67K | $6.88 | −$66.6K | −13.1%64.2K after | 2 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in Jounce Therapeutics, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 5,300,087 | $9.81M | 1.46% | +5,300,087 | New |
| Deep Track Capital, LP | 4,259,653 | $7.88M | 0.34% | 00.0% | Unchanged |
| Tudor Investment Corp Et Al | 3,160,841 | $5.85M | 0.11% | +3,160,841 | New |
| Opaleye Management Inc. | 2,880,000 | $5.33M | 1.60% | +2,880,000 | New |
| BlackRock Inc. | 2,546,289 | $4.71M | 0.00% | −25,167−1.0% | Reduced |
| Vanguard Group Inc | 2,107,305 | $3.90M | 0.00% | +474,127+29.0% | Added |
| Erste Asset Management GmbH | 1,559,587 | $2.89M | 0.06% | +100,000+6.9% | Added |
| JPMorgan Chase & Co | 1,136,847 | $2.10M | 0.00% | +886,639+354.4% | Added |
| BML Capital Management, LLC | 1,087,961 | $2.01M | 1.74% | +1,087,961 | New |
| Ardent Capital Management, Inc. | 923,463 | $1.71M | 1.23% | +923,463 | New |